Technical Analysis for OKUR - OnKure Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 16.00 | -2.38% | -0.39 |
OKUR closed down 2.38 percent on Wednesday, November 20, 2024, on 36 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Bullish Engulfing | Bullish | -2.38% | |
| Crossed Above 200 DMA | Bullish | -2.38% | |
| Outside Day | Range Expansion | -2.38% | |
| Gapped Down | Weakness | -2.38% | |
| Lower Bollinger Band Touch | Weakness | -2.38% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| 200 DMA Resistance | about 20 hours ago |
| 200 DMA Support | about 20 hours ago |
| Down 2 % | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Personalized Medicine Drug Design
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Personalized Medicine Drug Design
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 77.6 |
| 52 Week Low | 9.801 |
| Average Volume | 54,020 |
| 200-Day Moving Average | 16.27 |
| 50-Day Moving Average | 16.68 |
| 20-Day Moving Average | 16.98 |
| 10-Day Moving Average | 16.79 |
| Average True Range | 1.12 |
| RSI (14) | 39.76 |
| ADX | 31.61 |
| +DI | 7.13 |
| -DI | 21.67 |
| Chandelier Exit (Long, 3 ATRs) | 15.66 |
| Chandelier Exit (Short, 3 ATRs) | 18.07 |
| Upper Bollinger Bands | 18.19 |
| Lower Bollinger Band | 15.76 |
| Percent B (%b) | 0.1 |
| BandWidth | 14.27 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.1926 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.66 | ||||
| Resistance 3 (R3) | 16.70 | 16.51 | 16.55 | ||
| Resistance 2 (R2) | 16.51 | 16.35 | 16.50 | 16.51 | |
| Resistance 1 (R1) | 16.26 | 16.24 | 16.17 | 16.22 | 16.48 |
| Pivot Point | 16.07 | 16.07 | 16.03 | 16.06 | 16.07 |
| Support 1 (S1) | 15.82 | 15.91 | 15.73 | 15.78 | 15.52 |
| Support 2 (S2) | 15.63 | 15.80 | 15.62 | 15.49 | |
| Support 3 (S3) | 15.38 | 15.63 | 15.45 | ||
| Support 4 (S4) | 15.34 |
